Company Filing History:

22 out of 102

Fujirebio Inc.

patents

2 out of 31

Fujirebio Kabushiki Kaisha

Years Active: 1987-2004

Loading Chart...

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6812252 - Acylsulfonamide derivatives (2004-11-02),

2. 6555584 - Acylsulfonamide derivative (2003-04-29),

3. 6339089 - Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same (2002-01-15),

4. 6060602 - Compounds for producing 2-naphthamide derivative (2000-05-09),

5. 5965538 - Azapeptide derivative (1999-10-12),

6. 5917046 - Method for producing 2-naphthamide derivative, and compounds for (1999-06-29),

7. 5877333 - 1,2-dioxetane derivatives (1999-03-02),

8. 5859244 - 1,4-dihydropyridine derivatives and methods of producing the same (1999-01-12),

9. 5840977 - Methods of producing pantothenic acid derivative and its starting (1998-11-24),

10. 5837687 - Azapeptide derivative (1998-11-17),

11. 5763614 - 1,4-dihydropyridine derivatives and methods of producing the same (1998-06-09),

12. 5731445 - 1,2- Dioxetane derivatives (1998-03-24),

13. 5719298 - Methods of producing pantothenic acid derivative and its starting (1998-02-17),

14. 5714613 - Method of producing 2-naphthamide derivative, and compounds for (1998-02-03),

15. 5696268 - 1, 4-Dihydropyridine derivatives and methods of producing the same (1997-12-09),

Title: Hiroshi Ikawa: Innovating Hypoglycemic Treatments from Tokyo

Introduction

Hiroshi Ikawa is a prominent inventor based in Tokyo, Japan, recognized for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 26 patents, Ikawa has focused on developing innovative solutions to improve health outcomes, particularly in the realm of hypoglycemic agents.

Latest Patents

Among Ikawa's latest inventions are novel acylsulfonamide derivatives. These compounds, including 4-(3-trifluoromethyl)phenylethynyl-N-(2-(5-ketohexanoylamino)sulfonylphenyl)benzamide and 4-(3-trifluoromethyl)phenylethynyl-N-(2-(2-propyloxyacetylamino)sulfonylphenyl)benzamide, have been shown to exhibit hypoglycemic effects that are equal to or superior to traditional hypoglycemic agents. Notably, these derivatives are free from the side effects associated with conventional glitazone compounds, making them a promising option for diabetes treatment.

Career Highlights

Ikawa has made significant strides in his career, working with esteemed companies such as Fujirebio Inc. and Fujirebio Kabushiki Kaisha. His research and innovation in these organizations have greatly advanced the development of new medical therapies.

Collaborations

Collaborating with eminent coworkers like Tetsuaki Yamaura and Masakatsu Matsumoto, Ikawa has fostered a dynamic environment for innovation. These collaborations have played a crucial role in enhancing the research capabilities and outputs of their projects, leading to effective solutions in healthcare.

Conclusion

Hiroshi Ikawa stands out as a remarkable inventor whose work has the potential to transform the management of diabetes. His ongoing dedication to research and development not only reflects his innovative spirit but also contributes significantly to public health and well-being. As he continues to explore new avenues within pharmaceutical innovations, the medical field eagerly anticipates the future breakthroughs he will achieve.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com